Can CAR-T Be Optimized for Multiple Myeloma?
To tweak CAR-T therapies for myeloma, researchers are trying to repurpose a failed Alzheimer’s drug and are extracting patients’ T cells sooner.
Multiple Myeloma
Response-Adapted Intensification in Multiple Myeloma After Suboptimal Response to Induction
Patients who received intensification treatment experienced longer progression-free survival compared with patients receiving maintenance treatment.
Triple-Drug Induction Therapy Yields Sustained Responses in Multiple Myeloma
Patients receiving the 3-drug treatment experienced increasing rates of complete response and measurable residual disease from induction through consolidation.
Hematologic Scoring System Predicts Survival in Multiple Myeloma
A hematologic score based on specific blood parameters was evaluated for its potential to predict survival in patients with newly diagnosed multiple myeloma.
Treosulfan May Offer a New Standard for Prehematopoietic Stem Cell Transplantation Conditioning
Patients receiving treosulfan and fludarabine experienced improved event-free and overall survival compared with patients receiving busulfan and fludarabine.
FDA Proposal Threatens Transparency on Cancer Drug Safety and Efficacy
FDA documents have been a trove of information for researchers, leading to new insights about the safety and efficacy of a drug. An FDA proposal could end that.
Racial Disparities Affect Myeloma Treatment, Though Survival May Be Similar
Time to initiation of therapy was significantly longer for black and Hispanic patients compared with white patients.
Adherence to Other Oral Medications Declines Following Introduction of Oral Oncolytics
This study assessed levels of adherence to antihypertensive, lipid-lowering, and antidiabetic therapy in patients initiating oral oncology therapy for a hematologic cancer.
VTE Risk and Incidence in Hospitalized Patients With Blood Cancers
A new study aims to address the conundrum of coagulation risk in patients hospitalized for hematologic malignancies.
Everyone’s Conflicted: How Open Payments Did Little to Discourage Conflicts of Interest in Oncology
Since its inception, the Open Payments act does not appear to have prompted physicians to accept fewer payments from industry overall.
Next post in General Oncology
